Here, in a prospective longitudinal study, we aim to test the hypotheses that (1) combinations of p-tau, VILIP-1, and YKL-40 increase the diagnostic accuracy for AD and MCI; (2) p-tau, VILIP-1, and YKL-40 have different correlations with Aβ pathology and with different clinical stages of AD; and (3) p-tau, VILIP-1, and YKL-40 have different correlations with other AD features, including cognitive decline, cerebral atrophy, and white matter hyperintensities (WMH). This evidence concerns the gene VSNL1 and Alzheimer disease.